|
1
|
Tandon R, Belmaker RH, Gattaz WF,
Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ and Olie JP:
Fleischhacker WW and Moeller HJ; Section of Pharmacopsychiatry,
World Psychiatric Association: World Psychiatric Association
Pharmacopsychiatry Section statement on comparative effectiveness
of antipsychotics in the treatment of schizophrenia. Schizophr Res.
100:20–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou
CF and Chaiyakunapruk N: Global economic burden of schizophrenia: A
systematic review. Neuropsychiatr Dis Treat. 12:357–373.
2016.PubMed/NCBI
|
|
3
|
Samara MT, Dold M, Gianatsi M,
Nikolakopoulou A, Helfer B, Salanti G and Leucht S: Efficacy,
acceptability, and tolerability of antipsychotics in
treatment-resistant schizophrenia: A network meta-analysis. JAMA
Psychiatry. 73:199–210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Owen MJ, Sawa A and Mortensen PB:
Schizophrenia. Lancet. 388:86–97. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suzuki T, Remington G, Mulsant BH, Rajji
TK, Uchida H, Graff-Guerrero A and Mamo DC: Treatment resistant
schizophrenia and response to antipsychotics: A review. Schizophr
Res. 133:54–62. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chwieduk CM and Keating GM: Paliperidone
extended release: A review of its use in the management of
schizophrenia. Drugs. 70:1295–1317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang SM, Han C, Lee SJ, Patkar AA, Pae CU
and Fleischhacker WW: Paliperidone: A review of clinical trial data
and clinical implications. Clin Drug Investig. 32:497–512. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nussbaum AM and Stroup TS: Paliperidone
for treatment of schizophrenia. Schizophr Bull. 34:419–422. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spina E and Cavallaro R: The pharmacology
and safety of paliperidone extended-release in the treatment of
schizophrenia. Expert Opin Drug Saf. 6:651–662. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Breedvel P, Benjnen JH and Schellens JH:
Use of P-glycoprotein and BCRP inhibitors to improve oral
bioavailability and CNS penetration of anticancer drugs. Trends
Pharmacol Sci. 27:17–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ueno M, Nakagawa T, Wu B, Onodera M, Huang
CL, Kusaka T, Araki N and Sakamoto H: Transporters in the brain
endothelial barrier. Curr Med Chem. 17:1125–1138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Begley DJ: ABC transporters and the
blood-brain barrier. Curr Pharm Des. 10:1295–1312. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vermeir M, Naessens I, Remmerie B, Mannens
G, Hendrickx J, Sterkens P, Talluri K, Boom S, Eerdekens M, van
Osselaer N and Cleton A: Absorption, metabolism, and excretion of
paliperidone, a new monoaminergic antagonist, in humans. Drug Metab
Dispos. 36:769–779. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Suzuki Y, Tsuneyama N, Fukui N, Sugai T,
Watanabe J, Ono S, Saito M and Someya T: Impact of the ABCB1 gene
polymorphism on plasma 9-hydroxyrisperidone and active moiety
levels in Japanese patients with schizophrenia. J Clin
Psychopharmacol. 33:411–414. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang JS, Ruan Y, Taylor RM, Donovan JL,
Markowitz JS and DeVane CL: The brain entry of risperidone and
9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J
Neuropsychopharmacol. 7:415–419. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jani M, Ambrus C, Magnan R, Jakab KT,
Beéry E, Zolnerciks JK and Krajcsi P: Structure and function of
BCRP, a broad specificity transporter of xenobiotics and
endobiotics. Arch Toxicol. 88:1205–1248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang JS, Zhu HJ, Markowitz JS, Donovan JL,
Yuan HJ and Devane CL: Antipsychotic drugs inhibit the function of
breast cancer resistance protein. Basic Clin Pharmacol Toxicol.
103:336–341. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tian Y, Qu BX, Yao Y and Zeng S:
Establishment of BCRP expressed pig kidney cell line LLC-PK1/BCRP
and its biological profile. Yao Xue Xue Bao. 47:1599–1604. 2012.(In
Chinese). PubMed/NCBI
|
|
19
|
Yan H, Zhang DY, Li X, Yuan XQ, Yang YL,
Zhu KW, Zeng H, Li XL, Cao S, Zhou HH, et al: Long non-coding RNA
GAS5 polymorphism predicts a poor prognosis of acute myeloid
leukemia in Chinese patients via affecting hematopoietic
reconstitution. Leuk Lymphoma. 58:1948–1957. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Feng B, Mills JB, Davidson RE, Mireles RJ,
Janiszewski JS, Troutman MD and de Morais SM: In vitro
P-glycoprotein assays to predict the in vivo interactions of
P-glycoprotein with drugs in the central nervous system. Drug Metab
Dispos. 36:268–275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boulton DW, DeVane CL, Liston HL and
Markowitz JS: In vitro P-glycoprotein affinity for atypical and
conventional antipsychotics. Life Sci. 71:163–169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim KA, Joo HJ, Lee HM and Park JY:
Influence of ABCB1 and CYP3A5 genetic polymorphisms on the
pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenet
Genomics. 24:35–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hoosain FG, Choonara YE, Tomar LK, Kumar
P, Tyagi C, du Toit LC and Pillay V: Bypassing P-glycoprotein drug
efflux mechanisms: Possible applications in pharmacoresistant
schizophrenia therapy. Biomed Res Int. 2015:4849632015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tian Y, Qian S, Jiang Y, Shen Q, Zheng J,
Zhou H and Zeng S: The interaction between human breast cancer
resistance protein (BCRP) and five bisbenzylisoquinoline alkaloids.
Int J Pharm. 453:371–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takada T, Suzuki H and Sugiyama Y:
Characterization of polarized expression of point- or
deletion-mutated human BCRP/ABCG2 in LLC-PK1 cells. Pharm Res.
22:458–464. 2005.Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M,
Pastan I and Gottesman MM: Biochemical, cellular, and
pharmacological aspects of the multidrug transporter. Annu Rev
Pharmacol Toxicol. 39:361–398, 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ambudkar SV, Dey S, Hrycyna CA,
Ramachandra M, Pastan I and Gottesman MM: Biochemical, cellular,
and pharmacological aspects of the multidrug transporter. Annu Rev
Pharmacol Toxicol. 39:361–98. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hrycyna CA, Ramachandra M, Ambudkar SV, Ko
YH, Pedersen PL, Pastan I and Gottesman MM: Mechanism of action of
human P-glycoprotein ATPase activity. Photochemical cleavage during
a catalytic transition state using orthovanadate reveals cross-talk
between the two ATP sites. J Biol Chem. 273:16631–16634. 1998.
|
|
28
|
Ozvegy-Laczka C, Köblös G, Sarkadi B and
Váradi A: Single amino acid (482) variants of the ABCG2 multidrug
transporter: Major differences in transport capacity and substrate
recognition. Biochim Biophys Acta. 1668:53–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shukla S, Robey RW, Bates SE and Ambudkar
SV: The calcium channel blockers, 1,4-dihydropyridines, are
substrates of the multidrug resistance-linked ABC drug transporter,
ABCG2. Biochemistry. 45:8940–8951. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eddabra L, Wenner T, El Btaouri H, Baranek
T, Madoulet C, Cornillet-Lefebvre P and Morjani H: Arginine 482 to
glycine mutation in ABCG2/BCRP increases etoposide transport and
resistance to the drug in HEK-293 cells. Oncol Rep. 27:232–237.
2012.PubMed/NCBI
|
|
31
|
de Leon J, Wynn G and Sandson NB: The
pharmacokinetics of paliperidone versus risperidone.
Psychosomatics. 51:80–88. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lindenmayer JP and Kaur A: Antipsychotic
management of schizoaffective disorder: A review. Drugs.
76:589–604. 2016. View Article : Google Scholar : PubMed/NCBI
|
